About REXAHN

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing the next generation of targeted therapeutics for the treatment of cancer.
Rexahn's clinical development programs target specific proteins that are selectively localized in human cancer cells and not in healthy tissues resulting in increased efficacy and reduced toxicity.


News

Rexahn Pharmaceuticals to Present Data on RX-3117 and Supinoxin(TM) at the 2015 American Association for Cancer Research Annual Meeting


Rexahn Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference in Tokyo, Japan


More


Portfolio